Lucid Diagnostics Inc. (LUCD)
NASDAQ: LUCD · Real-Time Price · USD
1.000
+0.044 (4.62%)
At close: Nov 20, 2024, 4:00 PM
1.030
+0.030 (3.00%)
After-hours: Nov 20, 2024, 7:44 PM EST
Lucid Diagnostics Revenue
Lucid Diagnostics had revenue of $1.17M in the quarter ending September 30, 2024, with 49.68% growth. This brings the company's revenue in the last twelve months to $4.19M, up 179.27% year-over-year. In the year 2023, Lucid Diagnostics had annual revenue of $2.43M with 544.03% growth.
Revenue (ttm)
$4.19M
Revenue Growth
+179.27%
P/S Ratio
11.10
Revenue / Employee
$59,843
Employees
70
Market Cap
53.99M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Precision BioSciences | 75.10M |
Exagen | 55.75M |
Cytosorbents | 37.74M |
BGM Group | 29.87M |
Aadi Bioscience | 25.07M |
Kronos Bio | 9.87M |
Shattuck Labs | 6.44M |
Affimed | 6.29M |
LUCD News
- 1 day ago - Lucid Diagnostics Submits Clinical Evidence Package to MolDX Seeking Medicare Coverage for EsoGuard® Esophageal DNA Test - PRNewsWire
- 3 days ago - Lucid Diagnostics to Present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum - PRNewsWire
- 7 days ago - Lucid Diagnostics Inc. (LUCD) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 8 days ago - Lucid Diagnostics Provides Business Update and Third Quarter 2024 Financial Results - PRNewsWire
- 14 days ago - Lucid Diagnostics' ESOGUARD BE-1 Prospective Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing Accepted for Peer-Reviewed Publication - PRNewsWire
- 16 days ago - Lucid Diagnostics Expands Direct Contracting Initiative with Multiple Programs Focused on Near-Term Revenue Drivers - PRNewsWire
- 22 days ago - Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on November 13, 2024 - PRNewsWire
- 5 weeks ago - Lucid Diagnostics Receives Notice of Allowance for Key Patent Underlying Its EsoGuard Esophageal DNA Test - PRNewsWire